These findings have been confirmed by the ALICE-2 study and others, suggesting that the analysis of polymorphisms in VEGFR, VEGFA, and VEGFC can be useful to identify HCC patients less likely to benefit from sorafenib [60,67]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.